thalidomide has been researched along with Carcinoma, Anaplastic in 18 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to evaluate the incidence of adverse events (AEs) in female dogs diagnosed with advanced clinical stage mammary gland neoplasms following treatment with thalidomide." | 5.43 | Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas. ( Amorim, RL; Camargo Nunes, F; Carneiro, RA; Cassali, GD; de Campos, CB; Fialho Ligório, S; Lavalle, GE, 2016) |
| "Lenalidomide is an oral immunomodulatory drug (IMiD) approved in the United States for patients with MM." | 5.42 | A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide. ( Qian, W; Wang, B; Xu, G; Yang, M, 2015) |
| "To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment." | 3.88 | Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. ( Burman, P; Dekkers, OM; McCormack, A; Petersenn, S; Popovic, V; Raverot, G; Trouillas, J, 2018) |
| "Forty patients with Stage IC-IV ovarian cancer were randomly assigned to receive either carboplatin (AUC 7) intravenously every four weeks for up to six doses (n = 20) or carboplatin at the same dose and schedule, plus thalidomide 100 mg orally daily for six months (n = 20)." | 2.76 | A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis. ( Blann, AD; Braybrooke, JP; Ganesan, TS; Han, C; Jenkins, A; Kaur, K; Madhusudan, S; Muthuramalingam, SR; Perren, T; Wilner, S, 2011) |
| "The aim of the study was to evaluate the incidence of adverse events (AEs) in female dogs diagnosed with advanced clinical stage mammary gland neoplasms following treatment with thalidomide." | 1.43 | Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas. ( Amorim, RL; Camargo Nunes, F; Carneiro, RA; Cassali, GD; de Campos, CB; Fialho Ligório, S; Lavalle, GE, 2016) |
| "Lenalidomide is an oral immunomodulatory drug (IMiD) approved in the United States for patients with MM." | 1.42 | A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide. ( Qian, W; Wang, B; Xu, G; Yang, M, 2015) |
| "Thalidomide has been reported to have anti-angiogenic and antimetastatic effects." | 1.36 | Effect of thalidomide dithiocarbamate analogs on the intercellular adhesion molecule-1 expression. ( Abdou, BY; Agwa, HS; Guirgis, AA; Mohamed, AS; Talaat, RM; Zahran, MA, 2010) |
| "Thalidomide has no effect on tumor growth, but is also associated with increased VEGF and p53 expression." | 1.31 | Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. ( Bauer, AJ; Doniparthi, NK; Francis, GL; Patel, A; Ringel, MD; Saji, M; Terrell, R; Tuttle, RM, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 9 (50.00) | 24.3611 |
| 2020's | 2 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| He, L | 1 |
| Chen, C | 1 |
| Gao, G | 1 |
| Xu, K | 1 |
| Ma, Z | 1 |
| Zduniak, K | 1 |
| Gdesz-Birula, K | 1 |
| Woźniak, M | 1 |
| Duś-Szachniewicz, K | 1 |
| Ziółkowski, P | 1 |
| McCormack, A | 1 |
| Dekkers, OM | 1 |
| Petersenn, S | 1 |
| Popovic, V | 1 |
| Trouillas, J | 1 |
| Raverot, G | 1 |
| Burman, P | 1 |
| Polton, G | 1 |
| Finotello, R | 1 |
| Sabattini, S | 1 |
| Rossi, F | 1 |
| Laganga, P | 1 |
| Vasconi, ME | 1 |
| Barbanera, A | 1 |
| Stiborova, K | 1 |
| Rohrer Bley, C | 1 |
| Marconato, L | 1 |
| Hauser, P | 1 |
| Vancsó, I | 1 |
| Pócza, T | 1 |
| Schuler, D | 1 |
| Garami, M | 1 |
| Agarwal, N | 1 |
| Apolo, AB | 1 |
| Tsao, CK | 1 |
| Lee, KM | 1 |
| Godbold, JH | 1 |
| Soto, R | 1 |
| Poole, A | 1 |
| Gimpel-Tetra, K | 1 |
| Lowe, N | 1 |
| Oh, WK | 1 |
| Galsky, MD | 1 |
| Xu, G | 1 |
| Wang, B | 1 |
| Yang, M | 1 |
| Qian, W | 1 |
| Mizutani, S | 1 |
| Kuroda, J | 1 |
| Sasaki, N | 1 |
| Kiyota, M | 1 |
| Tatekawa, S | 1 |
| Tsukamoto, T | 1 |
| Maegawa, S | 1 |
| Chinen, Y | 1 |
| Shimura, Y | 1 |
| Nagoshi, H | 1 |
| Kobayashi, T | 1 |
| Horiike, S | 1 |
| Tando, S | 1 |
| Fushiki, S | 1 |
| Taniwaki, M | 1 |
| de Campos, CB | 1 |
| Lavalle, GE | 1 |
| Fialho Ligório, S | 1 |
| Camargo Nunes, F | 1 |
| Carneiro, RA | 1 |
| Amorim, RL | 1 |
| Cassali, GD | 1 |
| Grushka, JR | 1 |
| Ryckman, J | 1 |
| Mueller, C | 1 |
| Roessingh, Ade B | 1 |
| Walton, JM | 1 |
| St Vil, D | 1 |
| Laberge, JM | 1 |
| Bernard, C | 1 |
| Nguyen, VH | 1 |
| Puligandla, PS | 1 |
| Guirgis, AA | 1 |
| Zahran, MA | 1 |
| Mohamed, AS | 1 |
| Talaat, RM | 1 |
| Abdou, BY | 1 |
| Agwa, HS | 1 |
| Muthuramalingam, SR | 1 |
| Braybrooke, JP | 1 |
| Blann, AD | 1 |
| Madhusudan, S | 1 |
| Wilner, S | 1 |
| Jenkins, A | 1 |
| Han, C | 1 |
| Kaur, K | 1 |
| Perren, T | 1 |
| Ganesan, TS | 1 |
| Bauer, AJ | 1 |
| Terrell, R | 1 |
| Doniparthi, NK | 1 |
| Patel, A | 1 |
| Tuttle, RM | 1 |
| Saji, M | 1 |
| Ringel, MD | 1 |
| Francis, GL | 1 |
| JURET, P | 1 |
| AUBERT, C | 1 |
| DIPAOLO, JA | 1 |
| PAGNINI, G | 1 |
| DICARLO, R | 1 |
| Chacón, R | 1 |
| Tossen, G | 1 |
| Loria, FS | 1 |
| Chacón, M | 1 |
| Frank, RC | 1 |
| Kaplan, F | 1 |
| Nair, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-Center Phase Ib/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma[NCT01342172] | Phase 1/Phase 2 | 9 participants (Actual) | Interventional | 2011-03-31 | Terminated (stopped due to low accrual) | ||
| A Randomized Study Comparing Carboplatin and Thalidomide With Carboplatin Alone in Patients With Stage Ic - IV Ovarian Cancer[NCT00004876] | Phase 2 | 30 participants (Anticipated) | Interventional | 1999-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
MTD was determined by testing planned increasing doses up to 25 mg daily dose on days 1-14, starting at 10mg. MTD reflects the highest dose of drug that did not cause a Dose-Limiting Toxicity (DLT) in > 33% of participants. DLTs were defined as any lenalidomide-related Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE 4.0) Grade 3 or 4 adverse events (NCT01342172)
Timeframe: after 1 cycle (each cycle is 21 days)
| Intervention | mg (Number) |
|---|---|
| Lenalidomide | 10 |
"Best Overall Response to evaluate lenalidomide as maintenance treatment in patients achieving an objective response of either complete response or partial response following completion of 6 cycles of combination therapy.~Complete Response (CR) - CR of target lesions and no new lesions Partial Response (PR) -PR of target lesions and no new lesions Stable Disease (SD) - SD of target lesions and no new lesions Progression Disease (PD) - any status of target lesions and new lesions" (NCT01342172)
Timeframe: 168 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| CR | PR | |
| Lenalidomide | 1 | 2 |
Number of grade >=3 adverse events to assess the safety of combination therapy with gemcitabine, cisplatin plus lenalidomide as determined by the frequency and severity of adverse events as per the NCI Common Terminology for Adverse Events (CTCAE) version 4.0. (NCT01342172)
Timeframe: Day 1 and Day 8 of each treatment cycle; 21 days after the last dose of Lenalidomide
| Intervention | events (Number) | |
|---|---|---|
| Grade 3 | Grade 4 | |
| Lenalidomide | 28 | 7 |
"The objective response rate as determined by Response Evaluation Criteria in Solid Tumors (RECIST).~Complete Response (CR) Disappearance of all target lesions for a period of at least one month.~Partial Response (PR) At least a 30% decrease in the sum of the longest diameter of measures lesions (target lesions), taking as reference the baseline sum of the longest diameter.~Stable Disease (NR/SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since the treatment started.~Progressive Disease (PD) A 20% or greater increase in the sum of the longest diameter of measured lesions (target lesions), taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions" (NCT01342172)
Timeframe: After 2 cycles (a cycle is 21 days)
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| CR | PR | SD | PD | not evaluable | |
| Lenalidomide | 1 | 2 | 3 | 2 | 1 |
1 review available for thalidomide and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Ch | 2009 |
2 trials available for thalidomide and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug-Rela | 2014 |
A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2011 |
15 other studies available for thalidomide and Carcinoma, Anaplastic
| Article | Year |
|---|---|
ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.
Topics: Apoptosis; Azepines; bcl-X Protein; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; | 2020 |
The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Endothe | 2020 |
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016.
Topics: Adenoma; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemoth | 2018 |
Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Comb | 2018 |
[Antiangiogenic treatment of pediatric CNS tumors in Hungary with the Kieran schedule].
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemothera | 2013 |
A rare case of nasopharyngeal carcinoma in a patient with multiple myeloma after treatment by lenalidomide.
Topics: Carcinoma; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Nasophary | 2015 |
Quadruple Cancers of Non-producing Multiple Myeloma, Cholangiocellular Carcinoma, and Two Different Thyroid Cancers.
Topics: Aged; Bile Duct Neoplasms; Bortezomib; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; C | 2016 |
Absence of significant adverse events following thalidomide administration in bitches diagnosed with mammary gland carcinomas.
Topics: Animals; Carcinoma; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Female; Mammary Neoplasms, | 2016 |
Effect of thalidomide dithiocarbamate analogs on the intercellular adhesion molecule-1 expression.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Ehrlich Tumor; Cell Adhesion; Female; Intercel | 2010 |
Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Body Weight; Carcinoma; Cell Division; End | 2002 |
[Absence of carcinostatic effect of thalidomide with respect to 2 grafted tumors].
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Neoplasms, Experimental; Thalidomide | 1963 |
IN VITRO TEST SYSTEMS FOR CANCER CHEMOTHERAPY. II. CORRELATION OF IN VITRO INHIBITION OF DEHYDROGENASE AND GROWTH WITH IN VIVO INHIBITION OF EHRLICH ASCITES TUMOR.
Topics: Animals; Antineoplastic Agents; Arsenicals; Carbamates; Carcinoma; Carcinoma, Ehrlich Tumor; Colchic | 1963 |
[TREATMENT OF EXPERIMENTAL TUMORS WITH THALIDOMIDE].
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Mice; Multiple Myeloma; Neoplasms; Neoplasms, Experime | 1963 |
CASE 2. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide.
Topics: Adrenal Cortex Neoplasms; Adult; Angiogenesis Inhibitors; Carcinoma; Female; Humans; Thalidomide | 2005 |
Response of carcinoma of unknown primary site affecting bone to thalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma; Dexamethasone; Humans; Ma | 2005 |